Compound Detail
CHEMBL154139
TAGORIZINE 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL154139 |
| Name | TAGORIZINE |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | DVYCNKDRINREMB-WUKNDPDISA-N |
3
Targets
3
Activities
1
Assay Types
0
PK Parameters
5
Publications
5
Known Names
Molecular Properties
468.6
MW (Da)
4.71
ALogP
4
HBA
1
HBD
48.5
PSA (Ų)
0.35
QED
0
Ro5 Violations
10
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Activity Summary
IC50 3 meas. best 6.92
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Cavia porcellus CHEMBL369 | IC50 | 6.92 | 6.92 | 120.0 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase CHEMBL215 | IC50 | 5.31 | 5.31 | 4860.0 | 1 |
| Homo sapiens CHEMBL372 | IC50 | 4.47 | 4.47 | 34000.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Cavia porcellus | IC50 | = | 120.0 | nM | 6.92 | Anti-histaminic activity was measured in guinea pig trachea | 2465410 |
| Polyunsaturated fatty acid 5-lipoxygenase | IC50 | = | 4860.0 | nM | 5.31 | Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte | 2465410 |
| Homo sapiens | IC50 | = | 34000.0 | nM | 4.47 | Inhibitory activity against histamine release in human basophil | 2465410 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 2465410 | 10.1021/jm00123a012 | Rattus norvegicus | 2 |
| 2465410 | 10.1021/jm00123a012 | Polyunsaturated fatty acid 5-lipoxygenase | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 2465410 | 10.1021/jm00123a012 | Homo sapiens | 1 |
| 2465410 | 10.1021/jm00123a012 | Cavia porcellus | 1 |
Data from ChEMBL 36 via Core Engine